Lisata Therapeutics (LSTA) Competitors $2.57 +0.02 (+0.78%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSTA vs. KYTX, ORMP, CRBU, ANIX, CLLS, CLYM, PLRX, SNTI, GALT, and ADAGShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Kyverna Therapeutics (KYTX), Oramed Pharmaceuticals (ORMP), Caribou Biosciences (CRBU), Anixa Biosciences (ANIX), Cellectis (CLLS), Climb Bio (CLYM), Pliant Therapeutics (PLRX), Senti Biosciences (SNTI), Galectin Therapeutics (GALT), and Adagene (ADAG). These companies are all part of the "pharmaceutical products" industry. Lisata Therapeutics vs. Kyverna Therapeutics Oramed Pharmaceuticals Caribou Biosciences Anixa Biosciences Cellectis Climb Bio Pliant Therapeutics Senti Biosciences Galectin Therapeutics Adagene Kyverna Therapeutics (NASDAQ:KYTX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership. Does the media prefer KYTX or LSTA? In the previous week, Kyverna Therapeutics had 12 more articles in the media than Lisata Therapeutics. MarketBeat recorded 12 mentions for Kyverna Therapeutics and 0 mentions for Lisata Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.83 beat Lisata Therapeutics' score of 0.00 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Kyverna Therapeutics Positive Lisata Therapeutics Neutral Do institutionals & insiders hold more shares of KYTX or LSTA? 18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 22.0% of Kyverna Therapeutics shares are held by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, KYTX or LSTA? Kyverna Therapeutics has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Is KYTX or LSTA more profitable? Kyverna Therapeutics' return on equity of -51.12% beat Lisata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kyverna TherapeuticsN/A -51.12% -37.91% Lisata Therapeutics N/A -51.19%-45.16% Which has stronger valuation & earnings, KYTX or LSTA? Lisata Therapeutics has lower revenue, but higher earnings than Kyverna Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyverna Therapeutics$7.03M13.59-$60.37M-$3.38-0.65Lisata Therapeutics$1M21.54-$20.84M-$2.30-1.09 Do analysts recommend KYTX or LSTA? Kyverna Therapeutics presently has a consensus target price of $18.33, indicating a potential upside of 729.56%. Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 500.00%. Given Kyverna Therapeutics' higher possible upside, equities analysts plainly believe Kyverna Therapeutics is more favorable than Lisata Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in KYTX or LSTA? Lisata Therapeutics received 3 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users. Likewise, 93.33% of users gave Lisata Therapeutics an outperform vote while only 64.71% of users gave Kyverna Therapeutics an outperform vote. CompanyUnderperformOutperformKyverna TherapeuticsOutperform Votes1164.71% Underperform Votes635.29% Lisata TherapeuticsOutperform Votes1493.33% Underperform Votes16.67% SummaryKyverna Therapeutics beats Lisata Therapeutics on 12 of the 17 factors compared between the two stocks. Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.54M$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E Ratio-1.008.9226.8419.71Price / Sales21.54253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.436.466.794.50Net Income-$20.84M$143.98M$3.23B$248.18M7 Day Performance14.68%3.04%4.07%1.14%1 Month Performance9.65%7.44%12.52%15.20%1 Year Performance-16.94%-2.46%16.83%6.56% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics2.8096 of 5 stars$2.50-2.0%$15.00+500.0%-9.7%$21.54M$1M-1.0030Gap UpKYTXKyverna Therapeutics2.3587 of 5 stars$2.07-10.8%$18.33+785.7%-83.4%$89.46M$7.03M-0.6196News CoverageAnalyst RevisionGap UpORMPOramed Pharmaceuticals1.7549 of 5 stars$2.14-0.5%N/A-9.3%$87.42M$1.34M19.4510Earnings ReportCRBUCaribou Biosciences2.892 of 5 stars$1.05+11.9%$7.40+604.8%-64.9%$87.28M$9.92M-0.64100ANIXAnixa Biosciences1.7313 of 5 stars$2.70+1.9%$9.00+233.3%-8.1%$86.93M$210,000.00-6.925CLLSCellectis2.9011 of 5 stars$1.55-1.9%$6.67+330.1%-48.1%$86.16M$47.63M-1.19290CLYMClimb Bio2.5919 of 5 stars$1.27-1.6%$10.00+687.4%N/A$85.82MN/A-0.609News CoverageEarnings ReportAnalyst RevisionPLRXPliant Therapeutics4.2448 of 5 stars$1.35-2.2%$13.31+886.1%-90.9%$84.71M$1.58M-0.4090Positive NewsSNTISenti Biosciences1.696 of 5 stars$3.24+1.9%$12.00+270.4%-14.9%$84.50M$2.56M-0.214GALTGalectin Therapeutics1.2204 of 5 stars$1.33+3.9%$11.00+727.1%-59.2%$84.03MN/A-1.829Earnings ReportADAGAdagene2.319 of 5 stars$1.77flat$8.00+352.0%-40.0%$83.39M$103,204.000.00260 Related Companies and Tools Related Companies Kyverna Therapeutics Competitors Oramed Pharmaceuticals Competitors Caribou Biosciences Competitors Anixa Biosciences Competitors Cellectis Competitors Climb Bio Competitors Pliant Therapeutics Competitors Senti Biosciences Competitors Galectin Therapeutics Competitors Adagene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSTA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LSTA Stock Free LSTA Stock Alerts